Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET/MRI and plaque vulnerability
2016-002911-16Phase 3Terminated
- Sponsor
- Maastricht University Medical Center+
- Start
- Nov 2016
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of flutemetamol in atherosclerosis, sponsored by Maastricht University Medical Center+. Primary endpoint: Target-to-background ratio in symptomatic carotid artery plaque. Started Nov 2016; status: terminated.
02
Drugs
flutemetamol
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on 2016-002911-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002911-16.